OncoSec Medical (ONCSQ) Stock Price, News & Analysis

Company Overview

OncoSec Medical was a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its approach used electroporation, a technique that applies brief electrical pulses to help deliver therapeutic genetic material directly into tumors.

The company’s lead investigational therapy was tavokinogene telseplasmid, also known as TAVO, a DNA-based treatment designed to prompt tumor cells to produce interleukin-12 and stimulate an immune response. OncoSec studied TAVO in clinical trials, including research involving melanoma and combination treatment with other cancer therapies. It did not have an approved commercial product.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 62,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/05/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ONCSQ
• CIK: 1444307
• Web: www.oncosec.com
• Phone: (855) 662-6732
• Fax: 858-430-3832
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,970,000
• Free Float: 5,884,000
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: -30.04